• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    T

    Tennessee Retina

    EST. 1978
    324论文总数
    1.5万引用总数

    论文量&引用量时间轴

    机构学者

    论文(324)

    年份
    起
    –
    止
    排序
    1Retinal Fluid Quantification Using A Novel Deep Learning Algorithm in Patients Treated with Faricimab in the TRUCKEE Study
    Aamir Abdul Aziz,Hannah Khan, Tyler Rahimzadeh, Alan Sherif,Ashkan Abbey,David R. P. Almeida,Mark Barakat,Giulia Corradetti,Jordan M. Graff,Sara Haug,Veeral Sheth, Srini Vas R. Sadda,
    2026INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE(2026)引用:1
    引用
    AI阅读
    加入学术空间
    2The Hidden Economics of the Uveitis Specialist: A Practical Framework for Quantifying Direct, Downstream, and Strategic Contributions
    Akshay S. Thomas,Mark Dacey, Pauline Merrill,Laura J. Kopplin,Ogul E. Uner, Mitchell T. Allphin, Ananth Sastry,Eric B. Suhler,Veena Raiji

    To present a transparent, reproducible framework that practices and departments can use to quantify the full economic contribution of a uveitis specialist, whose value conventional billing based on professional collections or work relative value units (wRVUs) captures only in part. We developed a six-tier value model—direct clinical value, case-mix optimization, downstream/referral capture, strategic/option value, quality/avoided-cost value, and research and innovation value—and mapped each tier to defined metrics, data sources, and analytic methods (contribution-margin accounting, time-driven activity-based costing, downstream attribution, interrupted time series, and decision-analytic modeling), with a stepwise protocol for local implementation. We applied the framework to a hypothetical six-physician practice recruiting one fellowship-trained uveitis specialist. In an illustrative worked example, the framework attributed approximately $640,000 in annual practice-perspective clinical contribution to one uveitis specialist, rising to roughly $790,000 once clinical-trial revenue was included—about 3.4 times the $230,000 estimated from direct margin alone. The estimate remained positive (approximately +$460,000) even when the specialist was modeled as directly loss-making. Strategic, societal, and research-prominence value was substantial but reported separately to avoid double counting. As an illustrative model, the figures depend on local payer mix, facility ownership, and referral patterns. Valuing a uveitis specialist by direct collections alone may understate their economic contribution. A tiered framework that captures downstream and research value offers practices and departments a practical tool to measure that contribution locally and to inform recruitment, compensation, and resource allocation.

    2026Ocular Immunology and Inflammation(2026)
    引用
    AI阅读
    加入学术空间
    3Maribavir for Cytomegalovirus Retinitis: A Case Series and Review of the Literature
    Aumer Shughoury, Seema Emami, Eirini Kaisari, Rawan Kharouba,Akshay S Thomas,Debra A Goldstein, Timothy M Janetos

    Objective Therapy for vision-threatening CMV retinitis is often limited by drug resistance or systemic toxicity. Maribavir, a novel UL97 kinase inhibitor that has been FDA-approved for refractory CMV viremia, is a potential alternative to traditional antiviral therapy but remains understudied for CMV retinitis. The objective of this series is to describe the clinical courses and outcomes of patients with CMV retinitis after initiation of maribavir therapy. Design Retrospective case series. Subjects Six patients (11 eyes) with CMV retinitis from two tertiary uveitis centers. All were immunocompromised due to chemotherapy, immunotherapy, or AIDS and were initially treated with standard therapy (systemic and/or intravitreal ganciclovir, valganciclovir, or foscarnet) before developing drug resistance, toxicity, or intolerance prompting a transition to maribavir as alternative therapy. Intervention Oral maribavir 400mg twice daily. Main Outcome Measures Time to retinitis quiescence, visual acuity (VA), and adverse effects of therapy. Results 4/11 eyes had active retinitis upon initiation of maribavir and all achieved quiescence within 6 weeks. The remaining 7/11 eyes were already quiescent and remained so. VA remained stable or improved in all eyes. Notable clinical courses included (1) rapid decline in aqueous CMV titer and resolution of retinitis in a patient with multidrug-resistant CMV failing intravitreal ganciclovir/foscarnet; (2) a patient with UL54-resistant CMV and bilateral macula-involving retinitis rapidly achieving inactivity and preserved visual acuity on maribavir; and (3) successful substitution of maribavir in patients who were unable to continue conventional antiviral therapy due to drug-induced neutropenia or nephrotoxicity. Maribavir was generally well-tolerated, and only mild adverse effects were reported (dysgeusia, myalgia). Review of the literature identified 2 additional cases of patients with similar clinical courses achieving resolution of retinitis on maribavir. Conclusions In this descriptive case series, patients with multidrug-resistant CMV retinitis or intolerance to traditional antiviral therapy were observed to achieve or maintain quiescence of retinitis following initiation of maribavir. These findings suggest maribavir as a potential novel systemic option for challenging cases of CMV retinitis. Prospective studies are necessary to further characterize the efficacy and safety of maribavir for the treatment of CMV retinitis, as well as optimal duration of therapy after quiescence.

    2026AJO international(2026)
    引用
    AI阅读
    加入学术空间
    4The Financial Impact of Antivascular Endothelial Growth Factor Drug Durability
    Emily C. Davis, Tom Murickan, Ifrah Khurram,Sean T. Berkowitz, Charles Williard,Akshay S. Thomas

    Purpose: To examine the yearly cost of antivascular endothelial growth factor (anti-VEGF) therapy borne by patients and to assess the major contributors to patient cost. Methods: A retrospective, cross-sectional cost analysis was conducted of 29 250 insured patients in a single practice receiving anti-VEGF injections over a 21-month period between January 1, 2023, and September 30, 2024. Direct costs to the patient were abstracted, including patient copay and patient-responsible portions of imaging, medication, procedure, and visit costs; medication costs were based on average sales price. Transportation cost and opportunity cost associated with missed work were operationalized to estimate indirect costs, using age-stratified employment rates and median earnings from the United States Bureau of Labor Statistics for both patients and accompanying caregivers. Results: The mean (±SD) direct cost per visit was $91.72 ± $22.22. Indirect costs per visit varied by indication, with a mean indirect cost per visit of $97.89 for patients with neovascular age-related macular degeneration (AMD) and $164.44 for patients with diabetic macular edema (DME) for a half day of missed work, and $167.98 and $301.09, respectively, for a full day off work. Indirect costs accounted for 45.37% to 74.86% of total patient cost for a half day off, and 58.76% to 84.50% for a full day off. Relative to the baseline of 12 monthly bevacizumab injections received annually (half-day off scenario), the equivalent total patient cost accrued would correspond to a mean annual number of injections of 9.32 and 10.00 for aflibercept 2 mg, 11.09 and 11.35 for aflibercept 8 mg, and 9.05 and 9.78 for faricimab 6 mg in patients with neovascular AMD and patients with DME, respectively. Conclusions: Patient cost is driven more by visit frequency and its associated indirect costs than by drug price. Less frequent dosing with a more durable agent can therefore lower the total cost experienced by patients despite a higher acquisition price.

    2026Journal of VitreoRetinal Diseases(2026)
    引用
    AI阅读
    加入学术空间
    5Neoadjuvant Darovasertib in Uveal Melanoma Patients Undergoing Primary Local Therapy (Optimum-10): Phase 3 Trial.
    J. William Harbour, David Alan Reichstein,Martina Angi, Mandeep S. Sagoo,Roderick O'day, Marcus O. Butler,Heather May Shaw, Meredith McKean,Lotte S. Fog, Samuel T. Chao, John N. Waldron, Mwe,

    TPS9608 Background: Uveal melanoma (UM) is the most common intraocular malignancy and has high risk of metastatic progression and poor long-term survival. Standard treatment of the primary tumor includes enucleation (eye-removal), and radiation therapy including plaque brachytherapy (PB) and proton beam therapy, which can result in vision loss or removal of the eye. No approved neoadjuvant therapies exist that shrink the tumor or improve visual outcomes. Almost all UM tumors harbor GNAQ/GNA11 initiating mutations with downstream constitutive activation of protein kinase C (PKC). Darovasertib, a first-in-class oral PKC inhibitor tested in study OptimUM-09, has demonstrated the ability to reduce UM tumor size resulting in enucleation sparing in patients with large tumors, and radiation reduction in patients with medium sized tumors requiring PB. In addition, visual improvements have been observed not only during neoadjuvant therapy but also in the predicted risk of legal blindness post PB using a vision prognostication tool. Methods: OptimUM-10 is an ongoing phase 3, randomized, multicenter, open-label trial enrolling patients with primary non-metastatic UM. Eligible patients must have high metastatic risk (class 2 gene-expression profile, monosomy 3, or AJCC stage 3). Additionally, for the PB cohort, moderate to high risk of vision loss (> 30Gy predicted radiation dose to key visual structures) is required for eligibility. Major exclusion criteria include metastatic disease or extraocular tumor extension, prior UM primary treatment, attributes necessitating immediate enucleation, and relevant ocular comorbidities. The trial has two cohorts: Cohort 1 (n=330) includes patients with medium UM tumors where PB is the standard treatment. Cohort 2 (n=120) includes patients with large UM tumors where enucleation is the standard treatment. In each cohort, eligible patients are randomized 2:1 to receive neoadjuvant darovasertib (300 mg twice daily for up to six 28-day cycles) or standard-of-care treatment with PB (cohort 1) or enucleation (cohort 2). The primary endpoint for cohort 1 is the proportion of patients with loss of Early Treatment Diabetic Retinopathy Study Best-Corrected Visual Acuity of ≥15 letters (%VL15) from randomization, while in cohort 2 it is eye preservation rate. Across cohorts, the key secondary objective is to evaluate response rate with neoadjuvant darovasertib. Additional secondary endpoints include event-free survival and safety, as assessed by treatment-emergent adverse events and serious adverse events. Enrollment is ongoing, and results will determine whether OptimUM-10 may establish darovasertib prior to definitive PB as the first neoadjuvant treatment for primary UM to meaningfully reduce tumor burden and expand vision- and eye-preserving treatment options for patients. Clinical trial information: NCT07015190 .

    2026JOURNAL OF CLINICAL ONCOLOGY(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 324 篇论文

    合作机构(100)

    杜克大学合作论文 23
    Ophthalmic Consultants of Boston合作论文 22
    约翰斯·霍普金斯大学合作论文 17
    基因泰克合作论文 17
    斯坦福大学合作论文 16
    埃默里大学合作论文 15
    California Retina Consultants合作论文 13
    Retina Consultants of Houston合作论文 12
    Retina Vitreous Associates Medical Group合作论文 12
    美国国家卫生研究院合作论文 12

    机构统计